Cargando…
Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
INTRODUCTION: Diagnosis of Alzheimer's disease (AD) based on amyloid beta (A), pathologic tau (T), and neurodegeneration (N) biomarkers in peripheral fluids promises to accelerate clinical trials and intercept disease earlier. METHODS: Qualification of a Simoa plasma p217+tau assay was performe...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158165/ https://www.ncbi.nlm.nih.gov/pubmed/34095436 http://dx.doi.org/10.1002/dad2.12204 |
_version_ | 1783699827321733120 |
---|---|
author | Triana‐Baltzer, Gallen Moughadam, Setareh Slemmon, Randy Van Kolen, Kristof Theunis, Clara Mercken, Marc Kolb, Hartmuth C. |
author_facet | Triana‐Baltzer, Gallen Moughadam, Setareh Slemmon, Randy Van Kolen, Kristof Theunis, Clara Mercken, Marc Kolb, Hartmuth C. |
author_sort | Triana‐Baltzer, Gallen |
collection | PubMed |
description | INTRODUCTION: Diagnosis of Alzheimer's disease (AD) based on amyloid beta (A), pathologic tau (T), and neurodegeneration (N) biomarkers in peripheral fluids promises to accelerate clinical trials and intercept disease earlier. METHODS: Qualification of a Simoa plasma p217+tau assay was performed, followed by clinical utility evaluation in a cohort of 227 subjects with broad A and T spectrum. RESULTS: The p217+tau plasma assay was accurate, precise, dilution linear, and highly sensitive. All measured samples were within linear range of the assay, presented higher concentration in AD versus healthy controls (P < .0001), and plasma and cerebrospinal fluid levels correlated (r(2) = 0.35). The plasma p217+tau results were predictive of central T and A status (area under the curve = 0.90 and 0.90, respectively) with low false +/– rates. DISCUSSION: The assay described here exhibits good technical performance and shows potential as a highly accurate peripheral biomarker for A or T status in AD and cognitively normal subjects. |
format | Online Article Text |
id | pubmed-8158165 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81581652021-06-03 Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma Triana‐Baltzer, Gallen Moughadam, Setareh Slemmon, Randy Van Kolen, Kristof Theunis, Clara Mercken, Marc Kolb, Hartmuth C. Alzheimers Dement (Amst) Blood‐based Biomarkers INTRODUCTION: Diagnosis of Alzheimer's disease (AD) based on amyloid beta (A), pathologic tau (T), and neurodegeneration (N) biomarkers in peripheral fluids promises to accelerate clinical trials and intercept disease earlier. METHODS: Qualification of a Simoa plasma p217+tau assay was performed, followed by clinical utility evaluation in a cohort of 227 subjects with broad A and T spectrum. RESULTS: The p217+tau plasma assay was accurate, precise, dilution linear, and highly sensitive. All measured samples were within linear range of the assay, presented higher concentration in AD versus healthy controls (P < .0001), and plasma and cerebrospinal fluid levels correlated (r(2) = 0.35). The plasma p217+tau results were predictive of central T and A status (area under the curve = 0.90 and 0.90, respectively) with low false +/– rates. DISCUSSION: The assay described here exhibits good technical performance and shows potential as a highly accurate peripheral biomarker for A or T status in AD and cognitively normal subjects. John Wiley and Sons Inc. 2021-05-27 /pmc/articles/PMC8158165/ /pubmed/34095436 http://dx.doi.org/10.1002/dad2.12204 Text en © 2021 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Blood‐based Biomarkers Triana‐Baltzer, Gallen Moughadam, Setareh Slemmon, Randy Van Kolen, Kristof Theunis, Clara Mercken, Marc Kolb, Hartmuth C. Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma |
title | Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma |
title_full | Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma |
title_fullStr | Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma |
title_full_unstemmed | Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma |
title_short | Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma |
title_sort | development and validation of a high‐sensitivity assay for measuring p217+tau in plasma |
topic | Blood‐based Biomarkers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158165/ https://www.ncbi.nlm.nih.gov/pubmed/34095436 http://dx.doi.org/10.1002/dad2.12204 |
work_keys_str_mv | AT trianabaltzergallen developmentandvalidationofahighsensitivityassayformeasuringp217tauinplasma AT moughadamsetareh developmentandvalidationofahighsensitivityassayformeasuringp217tauinplasma AT slemmonrandy developmentandvalidationofahighsensitivityassayformeasuringp217tauinplasma AT vankolenkristof developmentandvalidationofahighsensitivityassayformeasuringp217tauinplasma AT theunisclara developmentandvalidationofahighsensitivityassayformeasuringp217tauinplasma AT merckenmarc developmentandvalidationofahighsensitivityassayformeasuringp217tauinplasma AT kolbhartmuthc developmentandvalidationofahighsensitivityassayformeasuringp217tauinplasma |